Medications Vyalev, Kisunla, and Leqembi

At Tampa Bay Neurology Center, we remain at the forefront of neurological care by offering specialized administration, coordination, and clinical oversight for groundbreaking therapies that transform disease management. Under the direction of Dr. Alamelu Murugappan, our practice provides comprehensive evaluation and monitoring for patients eligible for state-of-the-art disease-modifying treatments and advanced delivery systems. By integrating these novel therapies into personalized care plans, we aim to slow disease progression, optimize symptom control, and preserve independence for individuals navigating complex neurological conditions.

For patients living with advanced Parkinson’s disease who experience motor fluctuations, we provide expert care involving Vyalev™ ((foscarbidopa/foslevodopa). As a continuous 24-hour subcutaneous infusion, Vyalev delivers steady levodopa-based therapy morning, day, and night. This innovative non-surgical approach minimizes medication "wearing-off" periods and significantly improves "on" time without troublesome dyskinesia, offering a level of stability that traditional oral medications often cannot achieve as the disease progresses.

In memory care, our center offers access to anti-amyloid monoclonal antibody therapies designed for early-stage Alzheimer’s disease and mild cognitive impairment (MCI). We provide comprehensive screening, infusion coordination, and safety monitoring for Leqembi® (lecanemab) and Kisunla™ (donanemab). By directly targeting and clearing harmful amyloid plaques in the brain, these FDA-approved treatments work to slow down cognitive decline and preserve daily functional abilities. Dr. Murugappan guides patients and families through every step—from baseline neurocognitive testing and biomarker confirmation to routine safety monitoring—ensuring these advanced treatments are delivered safely and effectively.